AstraZeneca stock forecast
AstraZeneca's weighted forecast reaches 12,571.74 GBp in October 2027 and 13,714.80 GBp in October 2029. It hinges on replacement sales, launch uptake, margins and the valuation multiple.
Where could AstraZeneca's shares be by 2029?
The probability-weighted forecast points to moderate shareholder returns, with substantial execution risk. It reaches 12,571.74 GBp in October 2027, an 8% return including dividends, from today’s 11,892.00 GBp. It reaches 13,131.37 GBp in October 2028, a 15% return, and 13,714.80 GBp in October 2029, a 22% return.
The October 2029 range is wide: 6,541.08 GBp in the bear case to 22,391.36 GBp in the bull case. That spread reflects uncertainty over mature-product erosion, pipeline adoption, margins and the valuation multiple.
| Case | Probability | October 2027 | October 2028 | October 2029 |
|---|---|---|---|---|
| Bear | 25 % | 8625.35 (-25 %) | 7573.46 (-32 %) | 6541.08 (-39 %) |
| Base | 55 % | 13094.21 (+12 %) | 13482.59 (+18 %) | 13820.47 (+23 %) |
| Bull | 20 % | 16067.95 (+37 %) | 19112.89 (+65 %) | 22391.36 (+95 %) |
| Weighted | 100 % | 12571.74 (+8 %) | 13131.37 (+15 %) | 13714.80 (+22 %) |
What has to go right or wrong for AstraZeneca?
The October 2029 range runs from 6,541.08 GBp in the bear case to 22,391.36 GBp in the bull case. The base case is 13,820.47 GBp. Farxiga erosion and China price cuts must be offset by newer medicines during 2027–2029. Launch adoption, testing, reimbursement and sustained net revenue will decide whether the 2030 goals hold. Debt maturities in Q1 and Q2 2027 will compete with research, construction and launches for cash or refinancing capacity.
| FY2026 | FY2027 | FY2028 | FY2029 | |
|---|---|---|---|---|
| Revenue growth | 7.5 % (5.5 % / 8.5 %) | 7.0 % (3.0 % / 9.0 %) | 6.5 % (2.0 % / 9.0 %) | 6.5 % (1.0 % / 8.5 %) |
| Net margin | 17.5 % (15.4 % / 18.0 %) | 17.8 % (14.7 % / 19.0 %) | 18.0 % (14.2 % / 20.0 %) | 18.2 % (13.8 % / 20.8 %) |
| Earnings per share (GBp per AZN.L share) | 534 (461 / 555) | 580 (452 / 637) | 623 (444 / 729) | 669 (434 / 821) |
| Buybacks | 0.00 (0.00 / 0.00) | 0.00 (0.00 / 0.00) | 0.00 (0.00 / 0.00) | 0.00 (0.00 / 0.00) |
| Dividend per share (GBp per AZN.L share) | 249.87 (249.87 / 249.87) | 257.44 (252.14 / 265.01) | 265.01 (254.41 / 281.67) | 272.58 (256.68 / 299.09) |
How much cash does AstraZeneca really make?
Stock-based pay is an economic cost even though it is not paid entirely in cash. Subtracting the $719 million expense gives an analytical “real” free cash flow of $7,579 million. Receivables and inventory also require attention: faster collection, factoring and bank-backed drafts can change the timing of cash without changing the underlying sale.
| Year to Dec 2025 | Year to Dec 2024 | Year to Dec 2023 | Year to Dec 2022 | Year to Dec 2021 | |
|---|---|---|---|---|---|
| Cash from operations | 14,575 | 11,861 | 10,345 | 9,808 | 5,963 |
| Capital spending | 5,905 | 4,586 | 3,778 | 2,571 | 2,200 |
| Free cash flow (calculated) | 8,298 | 6,959 | 6,299 | 6,993 | 3,523 |
| Stock-based pay | 719 | 660 | 579 | 619 | 615 |
| Real free cash flow (after stock pay) (calculated) | 7,579 | 6,299 | 5,720 | 6,374 | 2,908 |
| Free cash flow left for shareholders (calculated) | 7,573 | 6,295 | 5,716 | 6,374 | 2,908 |
What does an investor pay for AstraZeneca today?
Revenue has risen across the five-year table, but the latest growth rate is slower than the acquisition-influenced 2021 and 2022 comparisons. Operating margin has improved, although reported profit still moves with impairments, restructuring and other exceptional items; net debt remains substantial. Diluted EPS has risen from a near-zero 2021 base, while the company’s own free cash flow per share is lower after stock-based pay. Valuation is 23.5x trailing P/E and 13.8x next-twelve-month P/E; free-cash-flow yield is 2.3%, dividend yield is 2.0%, and buybacks are absent.